All News

Although single-agent cediranib improved outcomes in differentiated thyroid cancer, the addition of lenalidomide does result in a clinically meaningful improvement.

The agent appears to be less effective among patients with HER2-low disease, according to final results from the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.

The addition of pembrolizumab to tisagenlecleucel also appears to yield inconclusive efficacy signals and did not augment cellular expansion among patients with diffuse large B-cell lymphoma in a phase 1b study.

Investigators of the phase 1/2 EPCORE NHL-1 trial plan to discuss their findings with global regulatory authorities to determine the next steps for epcoritamab in the treatment of relapsed/refractory follicular lymphoma.

Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.

The agent will be evaluated in a phase 1 study for patients with several myeloid malignancies, in which investigators will identify a recommended phase 2 dose.

18F-rhPSMA-7.3 was approved by the FDA for the detection of PSMA-positive lesions during PET/CT imaging in prostate cancer.

The oncolytic adenovirus VCN-01 is under investigation as a treatment for metastatic pancreatic ductal adenocarcinoma in the phase 2b VIRAGE trial.

An experimental cyclophosphamide-based prophylaxis regimen may also elicit a lower rate of chronic graft-versus-host-disease vs standard prophylaxis in patients with hematologic cancers.

Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.

Greater age may be an additional risk factor for fatigue among patients with prostate cancer receiving second generation antiandrogen agents, according to a recent systematic review.

Investigators anticipate sharing data from a phase 1/2a trial evaluating inobrodib on its own and in combination with pomalidomide and dexamethasone among patients with multiple myeloma at a future medical conference.

Data appear to support a tailored treatment approach with induction and post–autologous stem cell transplant consolidation daratumumab and CVRd in those with ultra-high–risk multiple myeloma.

Immunogene therapy quaratusugene ozeplasmid will be evaluated in combination with atezolizumab in a phase 1/2 trial for the treatment of small cell lung cancer.

Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.

The agent continues to produce ongoing responses in a cohort of patients with undifferentiated pleomorphic sarcoma or myxofibrosarcoma in the phase 2 ENVASARC trial.

Investigators expect to have a readout of topline data from the phase 2 OPTIMIZE-1 trial evaluating mitazalimab plus chemotherapy in metastatic pancreatic ductal adenocarcinoma in early 2024.

A recent Satellite Sessions program hosted by CancerNetwork® brought together experts from different Ochsner Health campuses to discuss the diversity of practices among care providers regarding patient interactions and treatment choices.

Experts present and discuss new findings from the CheckMate 9ER trial, evaluating nivolumab plus cabozantinib vs sunitinib in renal cell carcinoma.

ERAS-801 is under investigation as part of the phase 1 THUNDERBBOLT-1 trial in a population of patients with EGFR-mutant, recurrent glioblastoma.

Lindsay Morton, PhD, discusses the risks of developing secondary cancers among cancer survivors due to factors such as genetics and adverse effects associated with some chemotherapy- and radiotherapy-based regimens.

Topline data from the phase 3 KEYNOTE-585 trial, evaluating pembrolizumab in gastric and gastroesophageal junction adenocarcinoma, show a better rate of complete response following the experimental regimen vs chemotherapy alone.

Iopromide injection becomes the first FDA-approved contrast agent for visualizing known or suspected breast lesions in adult patients.

A pair of experts explore the expanding treatment landscape in non–small cell lung cancer for patients with EGFR exon 20 insertion mutations.

Gregory W. Roloff, MD, indicates that brexucabtagene autoleucel did not yield significant positive findings in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were MRD positive.

"We’ve learned from our colleagues in breast cancer that there are opportunities to leverage this hormonal axis with combinations [including] a CDK4/6 [inhibitor]."

A panel of experts, a patient, and her caregiver discuss her renal cell carcinoma diagnosis, the prevalent treatment options, and optimal strategies for patient education.

Findings from the phase 3 ADAM VTE trial indicate that apixaban yields lower rates of major bleeding compared with dalteparin as a thromboprophylactic treatment in patients with cancer.

Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.

Treatment with liso-cel produces low rates of severe cytokine release syndrome in relapsed/refractory mantle cell lymphoma and follicular lymphoma in the phase 1 TRANSCEND NHL 001 trial and the phase 2 TRANSCEND FL trial.